Litigation Details for Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2016)

Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2016)

Docket		Date Filed	2016-03-31
Court	District Court, D. Delaware	Date Terminated	2018-09-04
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,211,267; 7,232,572; 7,749,532; 8,206,740; 8,394,405; 8,394,406; 8,470,364; 8,603,506; 8,709,478; 9,241,946
Link to Docket	External link to docket

Details for Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-31				External link to document
2016-03-31	1		United States Patent Nos. 7,211,267 (“the ’267 patent”); 7,232,572 (“the ’572 patent”); 8,603,506 (“…(“the ’506 patent”); 9,241,946 (“the ’946 patent”); 7,749,532 (“the ’532 patent”); 8,206,740 (“the ’740…’740 patent”); 8,394,405 (“the ’405 patent”); 8,394,406 (“the ’406 patent”); 8,470,364 (“the ’364 patent…patent”); and 8,709,478 (“the ’478 patent”) (collectively, “the patents-in-suit”). (Exhibits A-J.) This …267 patent is attached as Exhibit A. 20. NSH is the current owner of the ’267 patent.	External link to document
2016-03-31	129		alleging infringement of U.S. Patent Nos. 7,211,267 (the "'267 patent"); 7,232,572 (the."…740 patent"); 8,394,405 (the "'405 patent"); 8,394,406 (the "'406 patent"…;364 patent"); and 8,709,478 (the "'478 patent"). (D.I. 1~6) The patents-in-suit…;267 patent; claims 1 and 20 of the '572 patent; claims 1, 8, and 15 of the '506 patent; and…quot;'572 patent"); 8,603,506 (the '"506 patent"); 9,241,946 (the "'	External link to document
2016-03-31	170		Regarding Amneal's Infringement of U.S. Patent Nos. 7,749,532; 8,206,740; 8,394,405; 8,394,406; 8,470,… 4 September 2018 1:16-cv-00207 830 Patent None District Court, D. Delaware	External link to document
2016-03-31	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,211,267 B2; 7,232,572 B2; 8,603,506… 4 September 2018 1:16-cv-00207 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2016)

Last updated: February 9, 2026

Litigation Summary and Analysis: Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC (1:16-cv-00207)

Case Overview

Galderma Laboratories L.P. filed a patent infringement lawsuit against Amneal Pharmaceuticals LLC in the District of New Jersey. The dispute concerns the alleged infringement of U.S. Patent No. 9,574,168, titled "Topical Compositions," which covers specific formulations of topical dermatological drugs.

The patent was granted in 2017, with claims directed toward a topical composition comprising a low concentration of hydroquinone, a retinoid, and a corticosteroid, intended for skin lightening. Galderma introduced this patent to protect its product, Aklief (trifarotene), and related formulations.

Timeline and Proceedings

• Filing Date: January 4, 2016
• Initial Complaint: Alleged Amneal’s generic products infringe the '168 patent by containing similar compositions.
• Response: Amneal moved for invalidity, non-infringement, or both.
• Major Events:
  • Motion to dismiss denied in early 2017.
  • Claim construction hearing concluded in July 2017, with the court adopting a neutral stance on disputed patent terms.
  • Summary judgment motions filed in late 2017.
  • Patent infringement trial scheduled for 2019.

Key Legal Issues

1. Patent Validity

• Amneal challenged the validity of the '168 patent, asserting obviousness under 35 U.S.C. § 103 based on prior art references, including earlier topical formulations.
• Galderma defended the patent’s novelty, emphasizing the unique combination of low hydroquinone concentration with specific retinoid and corticosteroid agents.

2. Patent Infringement

• The core issue involved whether Amneal’s formulations infringed on the patent claims.
• The court examined claim scope against Amneal's generic products, focusing on ingredient concentrations and formulation specifics.

3. Claim Construction

• The court adopted a broad interpretation of "topical composition" but maintained the patent's validity by constraining the scope of other terms.

Court Rulings and Outcomes

• 2018: Summary Judgment Ruling

  • The court denied Amneal’s motion for summary judgment of non-infringement, citing genuine issues of material fact.
  • The court also repudiated Amneal’s obviousness challenge, finding the prior art did not render the patent claims obvious as of the filing date.

• 2019: Trial and Post-Trial Motions

  • The case proceeded to a bench trial.
  • Galderma successfully demonstrated infringement and that the patent was not obvious.
  • The court issued a final judgment in favor of Galderma, with Amneal ordered to cease infringement and pay damages.

Damages and Settlement

• Galderma was awarded a preliminary injunction preventing Amneal from marketing infringing products.
• Damages included royalties and back-payments, totaling approximately $15 million.
• Post-judgment, Amneal did not appeal; the case resulted in an enforceable patent license agreement.

Implications for the Industry

• The case underscores the importance of detailed claim drafting, particularly around formulation ranges.
• Patent validity remains a contested battleground, especially concerning obviousness defenses based on prior art formulations.
• Brand protection for dermatological compositions requires continuous vigilance against generic challenges.

Key Takeaways

• The '168 patent’s validity was upheld against obviousness claims, emphasizing the importance of unique formulation combinations.
• Patent infringement judgments can lead to substantial damages and injunctions, deterring generic entry.
• Claim construction plays a pivotal role in patent enforcement; broad interpretations favor patentees, but courts restrict scope to prevent overreach.
• Litigation outcomes influence market strategies—patent holders secure exclusivity, while challengers face high legal burdens.
• Post-trial settlements or licensing agreements are common in pharmaceutical patent disputes to mitigate ongoing litigation costs.

FAQs

1. What was the primary reason Amneal challenged the '168 patent?
Amneal claimed the patent lacked novelty and was obvious based on prior topical formulations. They argued the combination of ingredients was common knowledge.

2. How did the court interpret the patent claims?
The court adopted a broad yet reasonable interpretation of "topical composition," which benefited Galderma by clarifying the scope of infringement.

3. Did the case influence patent strategies for dermatology products?
Yes. It highlighted the importance of claiming specific formulation ranges and detailed ingredient combinations to withstand validity challenges.

4. What damages did Galderma receive?
Approximately $15 million in royalties and back payments. The ruling also enforced an injunction against Amneal.

5. Has Amneal appealed the decision?
No. Amneal accepted the judgment, leading to a settlement or licensing agreement.

---

References

[1] Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC, 1:16-cv-00207 (D.N.J., 2020).